Russotti Gregory sold 534 Century Therapeutics shares at $2.05 per share on Sep 8, 2026, in an open-market transaction. The sale represented about 0.1% of the prior holding, while the reported post-transaction ownership was 511,785 shares, giving investors the stated scale of the transaction relative to Russotti Gregory’s position.
Key Highlights
- Russotti Gregory retained 511,785 Century Therapeutics shares after the transaction.
- The transaction record identifies Russotti Gregory under the designation “See Remarks.
- Russotti Gregory sold 534 shares of Century Therapeutics, Inc. The transaction was recorded at a stated price of $2.05 per share on Sep 8, 2026.
Century Therapeutics, Inc. (NASDAQ: IPSC) recorded a 534-share sale by Russotti Gregory at $2.05 per share on Sep 8, 2026.
Russotti Gregory’s Reported Position
The transaction involved a stated price of $2.05 per share. Russotti Gregory’s reported post-transaction position was 511,785 shares. These figures describe the sale price and the remaining shareholding separately.
Sale Represented 0.1% of Prior Holding
The sale represented about 0.1% of Russotti Gregory’s prior shareholding. That percentage is the stated comparison between the shares sold and the prior position. The reported ownership figure after the transaction was 511,785 shares.
FAQs
Q: How many Century Therapeutics shares did Russotti Gregory sell?
A: Russotti Gregory sold 534 shares of Century Therapeutics, Inc. The transaction was recorded at a stated price of $2.05 per share on Sep 8, 2026.
Q: What was the impact of Russotti Gregory’s IPSC stock transaction?
A: The transaction represented about 0.1% of Russotti Gregory’s prior shareholding. Reported ownership after the sale stood at 511,785 Century Therapeutics shares.
Q: At what price did Russotti Gregory sell Century Therapeutics shares?
A: The Century Therapeutics shares were sold at $2.05 per share. The transaction involved 534 shares and carried the open-market sale classification code S.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.